全文获取类型
收费全文 | 9300篇 |
免费 | 1034篇 |
国内免费 | 40篇 |
专业分类
耳鼻咽喉 | 72篇 |
儿科学 | 358篇 |
妇产科学 | 203篇 |
基础医学 | 1465篇 |
口腔科学 | 230篇 |
临床医学 | 1075篇 |
内科学 | 1742篇 |
皮肤病学 | 162篇 |
神经病学 | 752篇 |
特种医学 | 448篇 |
外科学 | 1315篇 |
综合类 | 242篇 |
一般理论 | 8篇 |
预防医学 | 953篇 |
眼科学 | 187篇 |
药学 | 601篇 |
中国医学 | 17篇 |
肿瘤学 | 544篇 |
出版年
2021年 | 111篇 |
2020年 | 66篇 |
2019年 | 108篇 |
2018年 | 171篇 |
2017年 | 136篇 |
2016年 | 121篇 |
2015年 | 180篇 |
2014年 | 261篇 |
2013年 | 367篇 |
2012年 | 395篇 |
2011年 | 389篇 |
2010年 | 282篇 |
2009年 | 266篇 |
2008年 | 353篇 |
2007年 | 386篇 |
2006年 | 405篇 |
2005年 | 360篇 |
2004年 | 346篇 |
2003年 | 343篇 |
2002年 | 388篇 |
2001年 | 325篇 |
2000年 | 304篇 |
1999年 | 279篇 |
1998年 | 216篇 |
1997年 | 163篇 |
1996年 | 182篇 |
1995年 | 139篇 |
1994年 | 159篇 |
1993年 | 123篇 |
1992年 | 201篇 |
1991年 | 217篇 |
1990年 | 196篇 |
1989年 | 212篇 |
1988年 | 186篇 |
1987年 | 198篇 |
1986年 | 181篇 |
1985年 | 189篇 |
1984年 | 136篇 |
1983年 | 100篇 |
1982年 | 75篇 |
1981年 | 65篇 |
1980年 | 71篇 |
1979年 | 81篇 |
1978年 | 66篇 |
1977年 | 68篇 |
1976年 | 53篇 |
1975年 | 74篇 |
1974年 | 62篇 |
1973年 | 65篇 |
1972年 | 57篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
2.
3.
4.
5.
P Avalos-Peralta† A Herrera† JJ Ríos-Martín‡ AM Pérez-Bernal† D Moreno-Ramírez† F Camacho† 《Journal of the European Academy of Dermatology and Venereology》2006,20(1):79-83
We report the case of a patient with a 13-year history of pemphigus vulgaris (PV) treated with immunosuppressive agents, prednisone and mycophenolate mofetil who had developed lesions of Kaposi's sarcoma (KS) on a sole plaque of PV that had been previously treated with intralesional injections of steroids. The lesions were surgically removed and polymerase chain reaction (PCR) demonstrated human herpesvirus-8 (HHV-8) DNA. There were neither recurrences nor later dissemination of KS following gradual decrease of the immunosuppressive therapy. We suggest that the treatment with intralesional steroids may have influenced the local reactivation of a latent infection of the virus, determining the appearance of this localized KS. 相似文献
6.
7.
8.
P Tugwell L Hart G Kraag A Park C Dok F Bianchi C Goldsmith W W Buchanan 《The Journal of rheumatology》1984,11(4):457-461
A crossover double-blind controlled trial was performed on 36 patients with rheumatoid arthritis to assess the necessity for serum salicylate monitoring in determining optimal dosage. There was no clinically or statistically significant increase in the clinical improvement of patients associated with serum monitoring but potentially toxic serum levels occurred without tinnitus when serum monitoring was not used. 相似文献
9.
10.
J. Duteil FA Rambert AM Pointeau P. Mangiameli and E. Assous 《Fundamental & clinical pharmacology》1991,5(8):695-708
The potential antidepressant effect of flerobuterol (dl-(fluoro-2 phenyl)-1 t-butylamino-2 ethanol), a new drug related to beta-adrenoceptor agonists, was evaluated and compared with imipramine and salbutamol using classical psychopharmacological tests in mice. Like imipramine and salbutamol, flerobuterol (0.5-32 mg kg-1, ip) fully prevented apomorphine (16 mg kg-1, sc)- and partly reversed reserpine- and oxotremorine-induced hypothermia. At higher doses (16-32 mg kg-1), flerobuterol enhanced the toxic effects of yohimbine. Unlike imipramine, flerobuterol and salbutamol did not reduce immobility duration in the behavioural despair test. Salbutamol and flerobuterol decreased locomotor activity. Flerobuterol did not induce mydriasis, did not prevent oxotremorine-induced tremors or salivary and lacrimal gland secretion and did not reduce reserpine-induced palpebral ptosis. Propranolol (8 mg kg-1, ip) but not alpha-methyl-paratyrosine (75 mg kg-1, ip) prevented the flerobuterol-induced antagonism of apomorphine-induced hypothermia. Our results suggest that flerobuterol demonstrates potential antidepressant activity, which could be related to beta-adrenoceptor activation in mice. 相似文献